Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.
Schaub C, et al. Among authors: banat m.
J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.
J Neurooncol. 2016.
PMID: 27193554